SNSE — Sensei Biotherapeutics, Inc. Dilution Risk Tracker

Sensei Biotherapeutics, Inc. (SNSE) has a DilutionScore of 49/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

The most significant dilution vector for SNSE is its shelf registration capacity of $200.0M. A shelf registration (typically an S-3 filing) gives a company pre-approved access to raise capital quickly without a traditional roadshow. The registered amount represents the maximum that can be raised — not necessarily what will be raised — but active shelves combined with tight cash positions are the pattern DilutionWatch monitors most closely.

DilutionWatch tracks over 25 SEC filing types for SNSE in real-time, scanning EDGAR every 60 seconds. A recent S-3 or registration statement filing appears in SNSE's filing history — this warrants monitoring for subsequent prospectus supplements (Form 424B), which indicate active capital raising. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch screener shows real-time score changes for SNSE alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.